• image

    “They did not know it was impossible,
    so they did it”
    M. Twain

    • Bartholomew, A., et al., 2002. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 30, 42-48.
    • Bonnomet, A., et al., 2012. Analysis of cell dispersion and migration by video-microscopy. Methods in Enzymology 505, 233-254.
    • Carrade, D.D., Affolter, V.K., Outerbridge, C.A., Watson, J.L., Galuppo, L.D., Buerchler, S., Kumar, V., Walker, N.J., Borjesson, D.L., (2011a). Intradermal injections of equine allogeneic umbilical cord-derived mesenchymal stem cells are well tolerated and do not elicit immediate or delayed hypersensitivity reactions. Cytotherapy 13, 1180-1192.
    • Carrade, D.D., Owens, S.D., Galuppo, L.D., Vidal, M.A., Ferraro, G.L., Librach, F., Buerchler, S., Friedman, M.S., Walker, N.J., Borjesson, D.L., (2011b). Clinicopathologic findings following intra-articular injection of autologous and allogeneic placentally derived equine mesenchymal stem cells in horses. Cytotherapy 13, 419-430.
    • Carrade, D.C, et al., 2012. Comparative analysis of the immunomodulatory properties of equine adult-derived mesenchymal stem cells. Cell Med 4, 1-11.
    • Colbath, A.C., et al., 2017. Autologous and allogeneic equine mesenchymal stem cells exhibit equivalent immunomodulatory properties in vitro. Stem Cells Dev 26, 503-511.
    • Daar, A.S., et al., 1984.. The detailed distribution of MHC Class II antigens in normal human organs. Transplantation 38, 293-298.
    • Da Silva-Mireilles, L., et al., 2009. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth factor Rev 20, 419-427.
    • De Schauwer, C., et al., 2012. In search for cross-reactivity to immunophenotype equine mesenchymal stromal cells by multicolor flow cytometry. Cytometry A 81, 312-323.
    • Di Nicola, M., et al., 2002. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99, 3838-3843.
    • Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F., Krause, D., Deans, R., Keating, A., Prockop, D., Horwitz, E., (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8, 315-317.
    • Dwyer, J.M., Johnson, C., 1981. The use of concanavalin A to study the immunoregulation of human T cells. Clin exp Immunol 46, 237-249.
    • Dyson, S.J., (2004). Medical management of superficial digital flexor tendonitis: a comparative study in 219 horses (1992-2000). Equine veterinary journal 36, 415-419.
    • Fang, B.J., Song, Y.P., Lin, Q.D., Zhang, Y.L., Cao, Y., Zhao, R.C.H., Ma, Y.F., (2007). Human adipose tissue-derived mesenchymal stromal cells as salvage therapy for treatment of severe refractory acute graft-vs.-host disease in two children. Pediatric Transplantation 11, 814-817.
    • Fülber, J., et al., 2016. Comparative study of equine mesenchymal stem cells from healthy and injured synovial tissues: an in vitro assessment. Stem Cell Res Ther 7, 35.
    • Guest, D.J., Smith M.R.W., Allen W.R., (2008). Monitoring the fate of autologous and allogeneic mesenchymal progenitor cells injected into the superficial digital flexor tendon of horses: Preliminary study. Equine Veterinary Journal 40, 178-181.
    • Herthel, D.J., (2001). Enhanced suspensory ligament healing in 100 horses by stem cells and other bone marrow components. Proceedings of American association of equine practitioners 47, 319-321.
    • Le Blanc, K., et al., 2002. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of major histocompatibility complex. Scand J Immunol 57, 11-20.
    • Murphy, K., 2012. Antigen recognition by B-cell and T-cell receptors. In: Janeways's Immunobiology.
    • Paterson, Y.Z., et al., 2014. Equine mesenchymal stromal cells and embryo-derived stem cells are immune privileged in vitro. Stem Cells Res Ther 5, 90.
    • Piggot, J.H., et al., 2013. Investigation of the immune response to autologous, allogeneic, and xenogeneic mesenchymal stem cells after intra-articular injection in horses. Vet Immunol Immunopathol 156, 99-106.
    • Ringden, O., Uzunel, M., Rasmusson, I., Remberger, M., Sundberg, B., Lonnies, H., Marschall, H.U., Dlugosz, A., Szakos, A., Hassan, Z., Omazic, B., Aschan, J., Barkholt, L., Le Blanc, K., (2006). Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 81, 1390-1397.
    • Schnabel, L.V., et al., 2014. Equine bone marrow-derived mesenchymal stromal cells are heterogeneous in MHC class II expression and capable of inciting an immune response in vitro. Stem Cell Res Ther 5, 13.
    • Spees, J.L., et al., 2016. Mechanisms of mesenchymal stem/stromal cell function. Stem Cell Res Ther 7, 125.
    • Tse, W. T., et al., 2003. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 75, 389-397.
    • Smith, R.K., (2008). Mesenchymal stem cell therapy for equine tendinopathy. Disability and rehabilitation 30, 1752-1758.